Research output: Contribution to journal › Review article › peer-review
Inhibitors of nuclease and redox activity of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1). / Laev, Sergey S.; Salakhutdinov, Nariman F.; Lavrik, Olga I.
In: Bioorganic and Medicinal Chemistry, Vol. 25, No. 9, 01.05.2017, p. 2531-2544.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Inhibitors of nuclease and redox activity of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1)
AU - Laev, Sergey S.
AU - Salakhutdinov, Nariman F.
AU - Lavrik, Olga I.
N1 - Copyright © 2017 Elsevier Ltd. All rights reserved.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Human apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1) is a multifunctional protein which is essential in the base excision repair (BER) pathway of DNA lesions caused by oxidation and alkylation. This protein hydrolyzes DNA adjacent to the 5′-end of an apurinic/apyrimidinic (AP) site to produce a nick with a 3′-hydroxyl group and a 5′-deoxyribose phosphate moiety or activates the DNA-binding activity of certain transcription factors through its redox function. Studies have indicated a role for APE1/Ref-1 in the pathogenesis of cancer and in resistance to DNA-interactive drugs. Thus, this protein has potential as a target in cancer treatment. As a result, major efforts have been directed to identify small molecule inhibitors against APE1/Ref-1 activities. These agents have the potential to become anticancer drugs. The aim of this review is to present recent progress in studies of all published small molecule APE1/Ref-1 inhibitors. The structures and activities of APE1/Ref-1 inhibitors, that target both DNA repair and redox activities, are presented and discussed. To date, there is an urgent need for further development of the design and synthesis of APE1/Ref-1 inhibitors due to high importance of this protein target.
AB - Human apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1) is a multifunctional protein which is essential in the base excision repair (BER) pathway of DNA lesions caused by oxidation and alkylation. This protein hydrolyzes DNA adjacent to the 5′-end of an apurinic/apyrimidinic (AP) site to produce a nick with a 3′-hydroxyl group and a 5′-deoxyribose phosphate moiety or activates the DNA-binding activity of certain transcription factors through its redox function. Studies have indicated a role for APE1/Ref-1 in the pathogenesis of cancer and in resistance to DNA-interactive drugs. Thus, this protein has potential as a target in cancer treatment. As a result, major efforts have been directed to identify small molecule inhibitors against APE1/Ref-1 activities. These agents have the potential to become anticancer drugs. The aim of this review is to present recent progress in studies of all published small molecule APE1/Ref-1 inhibitors. The structures and activities of APE1/Ref-1 inhibitors, that target both DNA repair and redox activities, are presented and discussed. To date, there is an urgent need for further development of the design and synthesis of APE1/Ref-1 inhibitors due to high importance of this protein target.
KW - Apurinic/apyrimidinic (AP) site
KW - Apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1)
KW - Base excision repair (BER)
KW - DNA repair
KW - E3330
KW - Inhibitors
KW - Lucanthone
KW - Methoxyamine
KW - BASE-EXCISION-REPAIR
KW - APURINIC-APYRIMIDINIC ENDONUCLEASE
KW - FACTOR-I
KW - SIGNALING PROTEIN APE1/REF-1
KW - ABASIC ENDONUCLEASE
KW - SMALL-MOLECULE INHIBITOR
KW - DNA-BINDING ACTIVITY
KW - CELL LUNG-CANCER
KW - HUMAN AP ENDONUCLEASE-1
KW - NF-KAPPA-B
KW - Humans
KW - DNA Repair/drug effects
KW - Enzyme Inhibitors/chemistry
KW - Oxidation-Reduction
KW - Neoplasms/drug therapy
KW - DNA-(Apurinic or Apyrimidinic Site) Lyase/antagonists & inhibitors
KW - Antineoplastic Agents/chemistry
KW - Animals
KW - Cell Line, Tumor
UR - http://www.scopus.com/inward/record.url?scp=85011068071&partnerID=8YFLogxK
U2 - 10.1016/j.bmc.2017.01.028
DO - 10.1016/j.bmc.2017.01.028
M3 - Review article
C2 - 28161249
AN - SCOPUS:85011068071
VL - 25
SP - 2531
EP - 2544
JO - Bioorganic and Medicinal Chemistry
JF - Bioorganic and Medicinal Chemistry
SN - 0968-0896
IS - 9
ER -
ID: 8681089